IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4239
Positioning
Market Dominance
Manufacturing
Consumer Goods
$10M
Yaniv Z. Sarig
Aterian, Inc. provides Artificial Intelligence Marketplace e-Commerce Engine, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. Its platform offers home and kitchen appliances; kitchenware; heating, cooling, and health and beauty products. The company also sells essential oils.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$ATER Aterian, Inc. | 34 | 56 | 17 | 10 | - | - | -56.6% | -31.9% | 58.0% | -16.1% | -17.3% | -32.0% | 0.0% | 77.0x | $10M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Aterian, Inc. (ATER) receives a "Avoid" rating with a composite score of 33.7/100. It ranks #4239 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Yaniv Z. Sarig
Chief Executive Officer
Labor Force
160
56
35
35
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for ATER
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ATER.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -56.6% (sector -2.5%)
GM 58% vs sector 43%, OM -16% vs sector 1%
Capital turnover N/A
Rev growth -32%, 6yr history
Interest coverage -7.4x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Aterian, Inc. with an Avoid rating, assigning a composite score of 33.7/100 and 1 out of 5 stars. Ranked #4239 of 7,333 stocks, ATER falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
With a quality score of 56/100, ATER shows adequate but unremarkable business quality. The company reports a return on equity of -56.6% (sector avg: -2.5%), gross margins of 58.0% (sector avg: 42.5%), net margins of -17.3% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
ATER registers a value score of just 17/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.26x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Aterian, Inc.'s investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -32.0% vs. a sector average of 5.9% and a return on assets of -31.9% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Aterian, Inc. is experiencing notably weak momentum with a score of just 10/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -32.0% year-over-year, while a beta of 1.50 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
ATER's stability score of 35/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.50 and a debt-to-equity ratio of 77.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Aterian, Inc.'s short interest score of 38/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.50), elevated leverage (D/E: 77.00x), micro-cap liquidity risk. At $10M (micro-cap), ATER carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Aterian, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4239 of 7,333 overall (42nd percentile). Key comparisons include ROE of -56.6% trailing the -2.5% sector median and operating margins of -16.1% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ATER currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (10) would have the largest impact on the composite score.
ROE 2181% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 37% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 1351% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Aterian, Inc. (ATER) as Avoid with a composite score of 33.7/100 at a current price of $0.57. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in quality (56th percentile) and stability (35th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (10th percentile) and value (17th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Aterian, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.7/100 places it at rank #4239 in our full 7,333-stock universe. At $10M in market capitalization, Aterian, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -32% combined with momentum at the 10th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 58% (+15.5pp vs sector) narrow to operating margins of -16% (-17.4pp vs sector) and net margins of -17.3%, yielding a gross-to-net conversion rate of -30%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.57, Aterian, Inc. is trading at a premium to fundamental value. Our value factor score of 17/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.3x, P/S of 0.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 58% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
The Avoid rating (composite 33.7/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -32% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -17.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (10th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a High uncertainty rating to Aterian, Inc.. Key risk factors include elevated market sensitivity (beta of 1.50), current negative profitability (net margin -17.3%), below-average price stability (35th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.50); current negative profitability (net margin -17.3%); below-average price stability (35th percentile); the combination of leverage (77% D/E) and thin margins (-17.3% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 35th percentile and quality factor at the 56th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 58% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Aterian, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-56.6%), negative profitability, weak asset returns (ROA -31.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Aterian, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Aterian, Inc. receives a Avoid rating with a composite score of 33.7/100 (rank #4239 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on Aterian, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Aterian, Inc. a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 12/20.
The strongest moat sources are margin superiority (12/20) and growth durability (9.3/20). GM 58% vs sector 43%, OM -16% vs sector 1%. Rev growth -32%, 6yr history. These pillars form the core of Aterian, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and economic value creation (2.5/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Aterian, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 58% providing a solid profitability foundation, declining revenues (-32%) that pressure the earnings outlook. The margin cascade from 58% gross to -16% operating to -17.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 56th percentile.
The margin profile shows gross margins of 58%, operating margins of -16%, net margins of -17.3%. Return metrics include ROE of -56.6% and ROA of -31.9%. Relative to the Manufacturing sector, gross margins are 15.5 percentage points above the sector median of 43%, and ROE of -56.6% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 77%, revenue growth of -32%. The sector median D/E is 0%, putting Aterian, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
High beta of 1.50 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081
SUMMIT, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER), a consumer products company, today announced that the Company’s Board of Directors has authorized the initiation of a formal process to evaluate and explore strategic alternatives aimed at maximizing shareholder value. These strategic alternatives could include, among other things, a potential sale of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. There can be

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. Cutera posted adjusted loss of $1.36 per share, compared to market estimates for a loss of 94 cents per share. The company’s quarterly sales came in at $49.540 million, versus expectations of $47.500 million, according to data from Benzinga Pro. Cutera shares dipped 26.5% to $1.6899 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Murano Global Investments PLC (NASDAQ: MRNO) shares jumped 147.5% to $23.94 after falling 46% on Thursday. Nova LifeStyle, Inc. (NASDAQ: NVFY) surged 120% to $4.0301 after gaining around 22% on Thursday. BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 50.4% to $0.2256 after the company reported better-than-expected fourth-quarter earnings results. IMAC Holdings, Inc. (NASDAQ: BACK) gained 41.1% to $1.8204. Summit Midstream Partners, LP (NYSE: SMLP) surged 36.1% to $26.45 after the company announced the sale of its Utica position for $625 million. Outlook Therapeutics, Inc. (NASDAQ: OTLK) gained 32.1% to $9.30 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD. GT Biopharma, Inc. (NASDAQ: GTBP) gained 27.6% to $4.86. Aemetis, Inc. (NASDAQ: AMTX) rose 21% to $6.21. Aemetis recently announced approval by the U.S. Citizenship and Immigration Services for a $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel, production plant, the dairy renewable natural gas project, the carbon sequestration project and energy efficiency upgrades to the Keyes ethanol plant. Foresight Autonomous Holdings Ltd. (NASDAQ: ...

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance. Clover Health Investments reported quarterly sales of $510.3 million which beat the analyst consensus estimate of $480.25 million by 6.26% and represents a 43.22% decrease over sales of $898.79 million the same period last year. Clover Health Investments shares climbed 11.2% to $0.8537 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Gaxos.ai Inc. (NASDAQ: GXAI) shares jumped 128.9% to $12.18 after the company announced it acquired the rights to use certain AI-enabled technology from Ultiself. Veritone, Inc. (NASDAQ: VERI) gained 52.4% to $2.6076 following strong sales results. NuCana plc (NASDAQ: NCNA) gained 50.2% to $0.5869 after the company was granted a US Patent for "Phosphoramidate Derivatives For Use In The Treatment Of Cancer; Especially In The Treatment Where The Patient Shows Resistance." The Beauty Health Company (NASDAQ: SKIN) rose 31.9% to $4.7350 after the company reported better-than-expected fourth-quarter revenue results. Arq, Inc. (NASDAQ: ARQ) gained 28.3% to $4.4522 after the company reported upbeat fourth-quarter results. MicroCloud Hologram Inc. (NASDAQ: HOLO) jumped 26.6% to $6.19. Kintara Therapeutics, Inc. (NASDAQ: KTRA) shares gained 26.2% to $0.1055. Nature's Sunshine Products, Inc. (NASDAQ: NATR) jumped 24.7% to $21.47 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 net sales guidance. Heron Therapeutics, Inc. (NASDAQ: HRTX) gained 24.7% to $2.9428 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $4 to $5. Li-Cycle Holdings Corp. (NASDAQ: LICY) shares gained 23.2% to $0.7233. Li-Cycle shares jumped 46% on Tuesday after the ...
Aterian, Inc.'s (NASDAQ:ATER) stock rose 24% last week, but insiders who sold US$189k worth of stock over the last year...